EP115 – Thyroid Cancer outcomes of South East Asian patients treated in Singapore

     

    Tan, Luke K.S.1; Tan, Ethan Te2;  Thio, S.T.3;
    1 National University of Singapore, Singapore
    2 Anglo-Chinese School (Independent), Singapore
    3 Luke Tan Ent Surgery Pte Ltd, Mount Elizabeth Medical Centre,  Singapore

     

    Background: The purpose of this study is to evaluate the quality and comprehensiveness  of patient care requiring treatment in thyroid cancer patients.  The cohort consists of multiple ethnicities residing in different countries.

    Methods:  A retrospect review from 1 January 2012 to 31 December 2016 was done of all thyroid surgeries performed by the senior author at Mount Elizabeth Medical Centre, Singapore. All cases of thyroid surgeries were included, with no exclusion criteria. The authors have no interest to declare or external funding received. The data was collected from the clinical notes, pathology and nuclear medicine reports.

    Results: The cohort consisted of Singaporeans, Malaysians, Indonesians, Vietnamese, Blangladeshi and others.  A total of 352 patients were entered in the study, and 42%(150) of patients had treatment for thyroid cancers. The recurrent nerve injury rate was 1.35 % and the permanent hypocalcaemia rate of 2 %.  86 % of patients with thyroid cancers underwent radio-iodine post thyroidectomy. The rate of distant metastatic rate was 4% at presentation.

    Discussion: Despite the varied nationalities and geographic residential differences, the uniformity of the outcome suggests that the care delivered was comprehensive. The rate of surgical complications suggests a satisfactory quality of surgical care. The high rate of radio-iodine compliance in patients with well differentiated thyroid malignancies indicates a satisfactory completion of initial treatment.

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    Steering Committee
    Rocco Bellatone, MD, Co-Chair
    Celestino Lombardi, MD, Co-Chair
    Gregory Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD